A Phase 3 interventional study of Difamilast and Placebo in Atopic Dermatitis, sponsored by Acrotech Biopharma Inc.. Completed at 39 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.
Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 10th largest by enrollment, is one of 3 that started in 2022, is one of 10 in phase 3, and was the 12th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15–70
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 3 mo–14 yrs
By country, each count listing its studies:
difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2022.
This study's enrollment of 153 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 177 across the 16 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Acrotech Biopharma Inc., one of the names counted as Aurobindo Pharma. Under that name alone:
Acrotech Biopharma Inc. is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Aurobindo Pharma has 2 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
2 of the studies testing difamilast in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173478Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | 2026-12 |
| NCT07184645Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing difamilast in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic dermatitis.
Important Inclusion Criteria:
Important Exclusion Criteria:
Etc.,
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1% Difamilast Ointment
Drug: Difamilast
Matching placebo
Drug: Placebo
Off-white ointment containing active ingredient, petrolatum and other ingredients
Matching Difamilast (Study drug) ointment without active ingradient
To evaluate the efficacy of twice-daily topical application of Difamilast ointment 1% compared to vehicle control in subjects ≥2 years of age with mild to moderate AD
The proportion of subjects achieving success on the the 5-point Investigator Global Assessment (IGA) of AD Severity score at Day 29, and the success is defined as as a score of Clear (0) or Almost clear (1), with at least a 2-grade improvement from Baseline on the 5-point IGA of AD Severity score at Day 29
Time frame: Baseline, Day 29
To further characterize the efficacy of Difamilast ointment 1% compared to vehicle control in subjects with mild to moderate AD
The proportion of subjects achieving an IGA of AD Severity score of Clear (0) or Almost clear (1) at Day 29; the proportion of subjects achieving success on the 5-point IGA of AD Severity score at Day 22; the proportion of subjects achieving success on the 5-point IGA of AD Severity score at Day 15 The proportion of subjects achieving success on the 5-point IGA of AD Severity score at Day 22 The proportion of subjects achieving success on the 5-point IGA of AD Severity score at Day 15
Time frame: Baseline, Day 15, Day 22 and Day 29
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Oct 2023, 12 months.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difamilast